Q32 Bio Inc.
Close on Oct 19, 2026
- Market cap
- $158.47M
- P/E (TTM)
- 3.2
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | – | $-0.44 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | – | $-0.54 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 10, 2026 | Before market open | $53.74M | $4.58 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | $-0.60 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | – | $-0.78 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | – | $-0.90 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 11, 2025 | Before market open | – | $-1.16 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | $-1.46 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 27, 2024 | After market close | – | – | – |
Press releases
Announcements Q32 Bio filed with the SEC
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger,
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Forward Looking Statements This presentation has been prepared by Q32
Other events · EX-99.1 to Form 8-K
Q32 Bio Announces Positive 36-Week Topline Results from Part B of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Q32 Bio Announces $55 Million Private Placement Financing
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Q32 Bio Announces $10.5 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Q32 Bio Sells Complement Inhibitor ADX-097
Material agreement · Agreement terminated · Acquisition or disposition completed · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA
Other events · EX-99.1 to Form 8-K
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial
Other events · EX-99.1 to Form 8-K
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Forward Looking Statements This presentation has been prepared by Q32
Regulation FD disclosure · EX-99.1 to Form 8-K
Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Forward Looking Statements This presentation has been prepared by Q32
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Q32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
Material agreement · Acquisition or disposition completed · Results of operations · New financial obligation · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
On March 25, 2024, we
Material agreement · Acquisition or disposition completed · Results of operations · New financial obligation · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
On March 25, 2024, we
Material agreement · Acquisition or disposition completed · Results of operations · New financial obligation · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K
Disclaimers Important Information for Investors This confidential
Regulation FD disclosure · EX-99.1 to Form 8-K
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Q32 Bio and Homology Medicines Announce Merger Agreement
Regulation FD disclosure · EX-99.1 to Form 8-K
Disclaimers Important Information for Investors This confidential
Regulation FD disclosure · EX-99.2 to Form 8-K
Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU
Regulation FD disclosure · EX-99.1 to Form 8-K
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
expectations about the transaction with Oxford Biomedica described herein, including anticipated benefits, anticipated payments, future business and market opportunities, anticipated growth resulting from the transaction and the anticipated timing
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K